PHS4 Epidemiology and Control of Tuberculosis in Ooty  by Patha, S. et al.
(mean(ml)SD 506.3193.4 vs 570.8222.4) with 12% after 6 hours, but the differ-
ence was not significant (p0,1494). The applied specific PNF exercise increased the
volume of the 6 hours postoperative bleeding with 5.6% (mean(ml)SD
514,16215,7 vs 543,05202,0); in 72 hours 5.3% (mean(ml)SD 1080,55327,6 vs
1138,44368,4); but the difference was not significant (p0,519 vs 0,4298). There
were not significant differences between the four groups regarding the postopera-
tive bleeding from all aspects. HGB and HTC reduction were near similar in all
groups; the differences were not significant among the groups. CONCLUSIONS:
This study proved that the 30° hip and knee flexion slightly increased the postop-
erative bleeding but it’s not a significant level, so it’s not suggested for blood-
saving. PNF exercise has slightly increased the postoperative bleeding but it is also
not a significant level. Maybe PNF exercise increases mildly the elimination of the
produced wound fluid.
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OBJECTIVES: To determine the population risk stratification based on the cost of
care (health resource use) in patients with chronic diseases in primary health care
(PC).METHODS:Multi-center observational design. We included all patients from 6
centers of PC that demanded assistance in 2011 managed by Badalona Serveis
Assistencials SA (health organization). The risk population was defined beginning
from the complexity (co-morbid chronic [CC]) and fragility (socio-demographic and
clinical criteria). Main measures: services (medical, paediatric), chronic co-morbid-
ity (CC) and direct cost model. From a group of experts identified the different
chronic conditions and population risk levels: Level 1 (no CC), level 2 (1-2 CC), level
3 (3-4 CC) and level 4 ( 5 CC). Fixed (operation) and variable costs were considered.
Statistical analysis: linear regression model (coefficient of determination [R2], de-
pendent variable: health care costs) and principal components, p0.05. RESULTS:
We included 84,002 patients, mean age 40.9 years, women: 53%. The total cost was
56.1 million / EUR. The average / unit cost: 675.3 euros. The cost for drugs was 41%.
Stratification levels: level 1 (N  36,859, 44.4%, €283.9), level 2 (N  32,644, 39.3%,
€694.8), Level 3 (N  10019, 12.1%, €1461.6, and level 4 (N  3568, 4.3%, €2331.2).
Musculoskeletal diseases (38.1%), mental (31.6%) and cardiovascular (30.4%) were
the most frequent, p 0.001. Predictive model (R2): age  23.4%, age-sex  24.1%,
age-sex-CC  41.8% (medical: 47.9%; Paediatrics: 15.1%, p 0.001). It details the
complexity and fragility of the patients for each level of stratification and clinical
services. CONCLUSIONS: The CC is associated with increased health care costs.
The number of co-morbidities explains much of the costs. Knowledge of the risk /
complexity / fragility of the patients should allow preventive intervention strate-
gies.
PHS3
ASSESSING THE SURVIVAL RATES AND ECONOMIC BURDEN OF PROSTATE
CANCER IN THE UNITED STATES VETERAN POPULATION
Baser O1, Xie L2, Huang A3, Li L3, Fritschel EK3, Wang L3
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research,
Ann Arbor, MI, USA, 3STATinMED Research, Dallas, TX, USA
OBJECTIVES: To assess the survival, demography, utilization, and cost patterns of
prostate cancer patients in the U.S. veteran population.METHODS:A retrospective
database analysis was performed using the Veterans Health Administration (VHA)
Medical SAS Datasets from October 1, 2007 to September 30, 2011. All U.S. veteran
beneficiaries diagnosed with prostate cancer were identified using International
Classification of Disease 9th Revision Clinical Modification (ICD-9-CM) diagnosis
code 185.xx. Survival was determined with the PROC LIFETEST procedure, and
descriptive statistics were calculated as means standard deviation (SD) and per-
centages to measure demographic, cost, and utilization distribution in the sample.
RESULTS: Among all study patients diagnosed with prostate cancer (n222,467),
the total survival rate reached 68.24% for patients age 39, 95.76% for those age
40-64, and 88.71% for those age 65 years. Patients most frequently resided in the
southern parts of the United States (34.85%) and the most common comorbidities
were hypertension (n131,790, 59.24%) and any tumor or other malignancy
(n106,803, 48.01%). The average number of inpatient (0.18, SD0.67), emergency
room (ER) (0.07, SD0.45), physician office (12.86, SD14.52) and outpatient visits
(13.73, SD15.30) were calculated for prostate cancer patients. Percentages of in-
patient (10.78%), ER (4.10%), physician office (99.89%), and outpatient visits (99.91%)
were also calculated. Patient expenditures were found to be $3,721 (SD$22,184) for
inpatient, $18 (SD$175) for ER, $5,012 (SD$8,693) for physician office and $5,385
(SD$9,417) for outpatient visits. CONCLUSIONS: The study suggests that the total
survival rate was considerably lower for the youngest age stratum of prostate
cancer veterans. However, more research is necessary to better understand ad-
verse events and side effects.
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OBJECTIVES: To evaluate the epidemiology and control of tuberculosis.METHODS:
A retrospective study was conducted for a period of 6 months on the all tubercu-
losis patients registered from 2008 to 2009 at Nilgiris district. The data was assessed
for studying the epidemiological trend of tuberculosis and to evaluate favorable
and unfavorable outcomes by studying patient demographics and treatment
outcomes. RESULTS: A total of 951 patients with tuberculosis (TB) were registered.
Among them, 473 cases were registered in 2008 and 478 cases were in 2009. The
average age of TB patients reported in 2008 with TB was 33.85( 18.67) years,
287(60.68%) males and 186 (39.32%) females. Among the 473 patients, there were
431(91.12%) cases newly diagnosed and the remaining 42(8.88%) were retreatment
cases. 245(51.79%) were pulmonary sputum positive, 94 cases (19.87%) were pul-
monary sputum negative and 134(28.32%) cases were extra-pulmonary tuberculo-
sis. The average age of the patients reported in 2009 was 34.71(17.63) years,
263(55.02%) males and 215(44.98%) females. Among the 478 patients, 427(89.33%)
newly diagnosed and 51(10.77%) retreatment cases. It was observed that
216(45.18%) patients were pulmonary sputum positive, 110 cases (23.01%) were
pulmonary sputum negative and 152 (31.79%) cases were extra-pulmonary TB.
Favorable Outcomes was observed that there was significant (p0.01) difference in
patients who received category-III treatment in the year 2008 (43.76%) and 2009
(34.85%) where majority of them were treatment completers. Unfavorable out-
comes was observed that there was no significant difference (p0.05) between the
unfavorable treatment outcomes of patient receiving the three categories of anti TB
treatments in 2008 and 2009. CONCLUSIONS: The treatment success rate of Di-
rectly Observed Treatment Short-Course during 2008 was 80.76% whereas in 2009 it
was 77.77% which was not achieved the World Health Assembly 1991 criteria for
monitoring TB control program. To conclude, the treatment success rate decreased
from 2008 to 2009.
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OBJECTIVES: To examine the economic burden, demographic and clinical charac-
teristics of ankylosing spondylitis (AS) in the U.S. veteran population.METHODS:A
retrospective database analysis was performed using the Veterans Health Admin-
istration (VHA) Medical SAS Datasets from October 1, 2007 to September 30, 2011.
Patients with AS were identified using International Classification of Disease
9thRevision Clinical Modification (ICD-9-CM) diagnosis code 720.0x. Survival was
determined with the PROC LIFETEST procedure, and descriptive statistics were
calculated as means standard deviation (SD) and percentages to measure demo-
graphics, costs and utilization distribution in the sample. RESULTS: In patients
identified with AS (n2,455), total survival rates in the 12-month follow-up period
were 98.1% for patients age 39, 97.0% for those age 40-64, and 89.6% for those age
65. The most common comorbidities in AS patients were hypertension (62.77%),
any tumor or malignancy (25.50%), and diabetes (24.11%). The percentage of pa-
tients who had follow-up inpatient visits was 14.34%, which translated into $6,240
in inpatient costs per patient. The percentage of patients who had follow-up out-
patient visits was 99.88%, which translated into $6,838 outpatient costs per patient.
The average number of inpatient (0.25, SD0.79), emergency room (ER) (0.10,
SD0.58), physician office (15.99, SD16.63) and outpatient visits (17.54, SD17.88)
were also calculated for AS patients. CONCLUSIONS: Comorbidities may play an
important role in the costs of AS treatment, since more than 20% of the study
population was also diagnosed with any combination of hypertension, diabetes,
and tumor or malignancy.
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OBJECTIVES: To estimate the incidence and prevalence of Alzheimer’s disease
based on rates of diagnosis in Taiwan for patients receiving health care treatment,
using data from the Taiwan Bureau of National Health Insurance (BNHI) Claims
database. METHODS: Data for this study were drawn from the Longitudinal Health
Insurance Database (LHID). The LHID contains all original claims data from a ran-
dom sample of 1 million individuals drawn from the larger BNHI database. The
BNHI database contains patient registration, diagnostic codes and health care use
claims for over 98% of the population of Taiwan. Subjects were included in this
study if they were 50 years or older and their records included a diagnostic code for
a primary or secondary diagnosis of Alzheimer’s disease between 2000 and 2005.
RESULTS: The number of new cases per year (annual incidence) with a diagnosis of
Alzheimer’s disease in Taiwan for those aged 50 or over was 5.58 per 1000 popula-
tion in 2005. The total number of cases (prevalence) for 2005 was 21.20 per 1000
population. When grouped according to age, the incidence and prevalence in-
creased with age. Incidence by age group was 0.86/1000 for ages 50-64, 6.17/1000 for
ages 65-74, 19.64/1000 for ages 75-84 and 43.31/1000 for those 85 and older. The
prevalence for the same period was 3.82/1000 for ages 50-64, 27.56/1000 for ages
65-74, 68.87/1000 for ages 75-84 and 120.14/1000 for those 85 and older.
CONCLUSIONS: The incidence and prevalence of Alzheimer’s disease increased
with age, at a similar rate seen in other studies. The results will be influenced by the
accuracy of diagnostic coding, which is likely to have been more accurate for inpa-
tients and less so for patients treated only in the outpatient setting, and because
they only include patients who received medical treatment.
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